The proposed 100% tariff on patented drugs in the United States is expected to significantly impact the global pharmaceutical sector. This move could increase the prices of patented medicines, ...

Did our AI summary help? Hetero has begun exporting generic versions of semaglutide, accelerating competition in the global market for diabetes and obesity medicines as demand for GLP‑1 therapies ...

https://www.thehindubusinessline.com/companies/natco-pharma-launches-generic-semaglutide-injection-in-india/article70764288.ece Copy Natco Pharma has launched the ...

Strides Pharma Science has agreed to acquire and in license a portfolio of branded generic medicines from Sandoz, strengthening its presence across Sub Saharan Africa. The deal, valued at about 12 ...

Persistent shortages (216 active at end‑2025) impose major operational costs (~$900M labor/year) and hit oncology, anesthesia, and emergency care, forcing substitutions and compounding with safety and ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

A terminal-based university course registration system built in Java, applying robust OOP principles and supporting roles like Students, Professors, Admins, and Teaching Assistants. Includes GPA ...

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines. Dr. Reddy’s, an Indian generic ...

FRANKFURT (Reuters) -Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss company's shares lower, as its top-selling drug comes ...

According to Nova One Advisor, the U.S. generic drugs market size is expected to be worth around 196.90 billion by 2034, increasing from USD 138.24 billion in 2024, representing a healthy CAGR of 3.6% ...